Antiviral Efficacy and Genotypic Resistance Patterns of Combination Therapy with Stavudine/Tenofovir in Highly Active Antiretroviral Therapy Experienced Patients
暂无分享,去创建一个
Stefano Bonora | Stefania Merli | Massimo Andreoni | A. Antinori | V. Tozzi | M. Andreoni | C. Perno | G. Carosi | M. Trotta | Valerio Tozzi | Mauro Zaccarelli | Maria Paola Trotta | Andrea Antinori | Carlo Federico Perno | A. Castagna | Giampiero Carosi | Antonella Castagna | P. Nasta | T. Bini | Giovanni Di Perri | Teresa Bini | T. Quirino | S. Bonora | Tiziana Quirino | Paola Nasta | Simona Landonio | S. Merli | S. Landonio | M. Zaccarelli | G. Perri
[1] F. Brun-Vézinet,et al. Effect of Zidovudine Resistance Mutations on Virologic Response to Treatment With Zidovudine or Stavudine, Each in Combination With Lamivudine and Indinavir , 2002, Journal of acquired immune deficiency syndromes.
[2] B. Clotet,et al. Safety and Efficacy of Once-Daily Didanosine, Tenofovir and Nevirapine as a Simplification Antiretroviral Approach , 2003, Antiviral therapy.
[3] M. Wulfsohn,et al. Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection , 2003, Annals of Internal Medicine.
[4] B. Larder,et al. Phenotypic Susceptibilities to Tenofovir in a Large Panel of Clinically Derived Human Immunodeficiency Virus Type 1 Isolates , 2002, Antimicrobial Agents and Chemotherapy.
[5] V. Abraira,et al. High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir , 2005, AIDS.
[6] V. Calvez,et al. Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level. , 2004, Journal of acquired immune deficiency syndromes.
[7] B. Clotet,et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine , 2005, AIDS.
[8] L. Naeger,et al. Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication Capacity , 2002, Antimicrobial Agents and Chemotherapy.
[9] M. Juan,et al. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load , 2004, AIDS.
[10] P. Anderson,et al. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. , 2004, AIDS.
[11] Joel E Gallant,et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.
[12] Y. Yazdanpanah,et al. Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine. , 2003, The Journal of antimicrobial chemotherapy.
[13] Jesús Santos,et al. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results , 2004, AIDS.
[14] M. Wainberg,et al. In vitro Selection and Characterization of HIV-1 with Reduced Susceptibility to PMPA , 1998, Antiviral therapy.
[15] Amalio Telenti,et al. Update of the Drug Resistance Mutations in HIV-1: 2005. , 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[16] J. Gallant,et al. Tenofovir disoproxil fumarate , 2003, Reactions Weekly.
[17] R. Schooley,et al. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF , 2002, AIDS.
[18] Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients. , 2005, Journal of acquired immune deficiency syndromes.
[19] M. Wulfsohn,et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. , 2004, The Journal of infectious diseases.
[20] P. Frissen,et al. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression , 2003, The Lancet.
[21] M. Wainberg,et al. Resistance Issues With New Nucleoside/Nucleotide Backbone Options , 2004, Journal of acquired immune deficiency syndromes.
[22] R. Schooley,et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study , 2002, AIDS.
[23] Thomas Lengauer,et al. Tenofovir Resistance and Resensitization , 2003, Antimicrobial Agents and Chemotherapy.
[24] S D Kemp,et al. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.
[25] F. Brun-Vézinet,et al. Genotypic Determinants of the Virological Response to Tenofovir Disoproxil Fumarate in Nucleoside Reverse Transcriptase Inhibitor-Experienced Patients , 2003, Antiviral therapy.
[26] J. Gatell,et al. Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine. , 2005, AIDS.